Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PPM1B | O75688 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21998228 | 0.87 | TDP1 (0.46) | TDP1KMT2AMAPK1HIF1ACHRNB2 | |
| SCHEMBL23808024 | 0.87 | TDP1 (0.46) | TDP1KMT2AMAPK1HIF1ACHRNB2 | |
| SCHEMBL711840 | 0.84 | MAPK1 (0.44) | TDP1KMT2AMAPK1HIF1ACHRNB2 | |
| SCHEMBL12959086 | 0.83 | NPC1 (0.53) | TDP1KMT2AMAPK1HIF1ACHRNB2 | |
| Benzoic Acid 2,3-Epoxypropyl Ester SCHEMBL5604855 | 0.82 | NPC1 (0.56) | TDP1MAPK1HIF1ACHRNB2CHRNA5 | |
| Benzoic Acid 2,3-Epoxypropyl Ester SCHEMBL14570069 | 0.82 | NPC1 (0.56) | TDP1MAPK1HIF1ACHRNB2CHRNA5 | |
| Benzoic Acid 2,3-Epoxypropyl Ester SCHEMBL133986 | 0.82 | NPC1 (0.56) | TDP1MAPK1HIF1ACHRNB2CHRNA5 | |
| Benzoic Acid 2,3-Epoxypropyl Ester SCHEMBL21245419 | 0.82 | NPC1 (0.56) | TDP1MAPK1HIF1ACHRNB2CHRNA5 | |
| SCHEMBL1931720 | 0.81 | PPM1B (0.44) | TDP1KMT2AMAPK1HIF1ACHRNB2 | |
| SCHEMBL7204759 | 0.81 | TDP1 (0.50) | TDP1KMT2AMAPK1HIF1ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030338-B2 | Method for producing 2-nitroimidazole derivative | POLA PHARMA INC. (JP) | 2011-10-04 | — | — | US | claimed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-11731959-B2 | Troxacitabine synthesis and crystal form thereof | BEIJING HEBABIZ BIOTECHNOLOGY CO., INC. (CN) | 2023-08-22 | — | — | US | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-11-03 | — | — | US | disclosed |
| US-20200247787-A1 | TROXACITABINE SYNTHESIS AND CRYSTAL FORM THEREOF | BEIJING HEBABIZ BIOTECHNOLOGY CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-10336780-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20190100541-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2019-04-04 | — | — | US | disclosed |
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2017-09-21 | — | — | US | disclosed |
| EP-1467990-B1 | PROCESS FOR PRODUCING DIOXOLANE NUCLEOSIDE ANALOGUE PRECURSORS | SHIRE BIOCHEM INC (CA) | 2012-03-07 | — | — | EP | disclosed |
| US-7442813-B2 | Process for producing dioxolane nucleoside analogues | SHIRE BIOCHEM INC. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1265890-B1 | STEREOSELECTIVE SYNTHESIS OF NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC (CA) | 2007-04-18 | — | — | EP | disclosed |
| US-5792773-A | L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection | YALE UNIVERSITY (US) | 1998-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100541-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | TDP1 2014/4885KMT2A 3925/4885MAPK1 3170/4885 |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | TDP1 2102/4885KMT2A 4295/4885MAPK1 2844/4885 |
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, NT5C, DUT | TDP1 1878/4885KMT2A 4244/4885MAPK1 2979/4885 |
| US-11731959-B2 | Troxacitabine synthesis and crystal form thereof | TBXAS1, TTPA, TBCB | TDP1 1851/4885KMT2A 1609/4885MAPK1 3959/4885 |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | TDP1 2000/4885KMT2A 4335/4885MAPK1 2890/4885 |
| US-10336780-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NT5C | TDP1 2002/4885KMT2A 4335/4885MAPK1 3026/4885 |
| US-20200247787-A1 | TROXACITABINE SYNTHESIS AND CRYSTAL FORM THEREOF | TBXAS1, TTPA, TBCB | TDP1 1851/4885KMT2A 1609/4885MAPK1 3959/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | TDP1 2000/4885KMT2A 4335/4885MAPK1 2890/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | TDP1 2000/4885KMT2A 4335/4885MAPK1 2890/4885 |
| US-20070197784-A1 | Process for producing dioxolane nucleoside analogues | NUDT1, DPYD, DUT | TDP1 565/4885KMT2A 4173/4885MAPK1 902/4885 |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | TDP1 2000/4885KMT2A 4335/4885MAPK1 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.